Qufeng Antispasmodic To Asthma Scattered (Wind Phlegm Wheezing) Patients With Pulmonary Function, FeNO Influence

Objective: To observe the antispasmodic for chronic scattered bronchial asthmaduration wind phlegm wheezing patients with pulmonary function, breath the influence ofnitric oxide. Methods:60patients with chronic duration with bronchial asthma windphlegm wheezing patients were randomly divided into the treatment group and controlgroup of30cases of30cases, both groups to hormone inhaled treatment, the treatmentgroup and give oral qufeng antispasmodic scattered.8weeks of treatment. Observe bothgroups of patients before and after treatment symptoms, signs, pulmonary function, breathnitric oxide changes. Results: treatment group patients before and after treatment meanthe FEV1%were77.13%,93.34%, and two more significant statistical difference (P <0.01), and the control group of patients before and after treatment FEV1%were84.56%,73.87%, is significant both statistical differences (P <0.05); The treatment group ofpatients before and after treatment mean FeNO were63.04ppb,32.17ppb, two moresignificant statistical difference (P <0.01), and the control group of patients before andafter treatment mean FeNO were59.04ppb,55.02ppb, two more no significant statisticaldifference (P>0.05). Conclusion: qufeng antispasmodic scattered chronic duration canimprove the bronchus asthma wind phlegm wheezing of patients with lung function, canreduce the duration asthma patients airway inflammation, bronchial hyperresponsivenessand breath nitric oxide level.